logo
Share SHARE
FONT-SIZE Plus   Neg

AVI BioPharma Gets FDA Approval To Proceed With AVI-7288 To Treat Marburg Virus

AVI BioPharma, Inc. (AVII) Tuesday announced that the U.S Food and Drug Administration, or the FDA, has granted approval to the company to proceed with a single oligomer, AVI-7288, in studies in both humans and non-human primates to support the safety and efficacy of post-exposure prophylaxis against Marburg virus infection.

The company stated that AVI-7288 is one of two components that make up AVI-6003.

The company further added that it will proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies planned to characterize the safety, tolerability and pharmacokinetics of multiple doses of the drug in healthy adult volunteers.

"While we have not seen any toxicity in humans to date with AVI-6003, by removing AVI-7287 we have a simpler development path and may improve the therapeutic window by evaluating a single action agent," said Chris Garabedian, president and CEO of AVI BioPharma. "We are pleased to be able to explore this single oligomer as a potentially safe and effective treatment against this lethal hemorrhagic fever virus."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A Brazilian judge has ordered all wireless phone carriers in the country to block WhatsApp after the Facebook-owned messaging service failed to comply with an order asking to turn over data related to a criminal investigation. According to reports, the app, which is used by over 100 million Brazilians,... Amazon.com Inc. intends to bring its free same-day delivery to the Bronx and Chicago's South Side areas. The online retailer's plans comes after severe criticism were raised that the company unfairly left out some predominantly black and Hispanic areas from its Prime service. An analysis done by... Sprint Corp., the third largest U.S. wireless carrier, on Tuesday reported a loss for the fourth quarter that widened from last year on one-time charges and lower revenues. The latest quarter's results include charges related to severance and lease exit costs, including the shutdown of legacy WiMAX service that will free up valuable spectrum and immediately lower network costs.
comments powered by Disqus
Follow RTT